AstraZeneca Sells US Rights over Gastroenterological Drug Entocort (Budesonide)

AstraZeneca Sells US Rights over Gastroenterological Drug Entocort (Budesonide)
AstraZeneca recently announced an agreement with Perrigo Company plc regarding the divestment of rights for Entocort® (budesonide) in the United States. Entocort is a locally-acting glucocorticosteroid considered a first-line therapy indicated for the induction and maintenance of clinical remission in patients with mild to moderate active Crohn’s disease and ulcerative colitis. The agreement is based on the

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *